Relapsing polychondritis, an underestimated dermatological urgency: case report and literature review.

Autor: Cuestas D; Dermatology Service, Samaritana University Hospital - ESE, Bogotá, Colombia.; Dermatology Program, El Bosque University, Bogotá, Colombia., Peñaranda E; Dermatology Service, Samaritana University Hospital - ESE, Bogotá, Colombia.; Dermatology Program, National University of Colombia, Bogotá, Colombia., Mora S; Rheumatology Service, Samaritana University Hospital - ESE, Bogotá, Colombia., Cortes C; Dermatology Service, Samaritana University Hospital - ESE, Bogotá, Colombia.; Dermatology Program, National University of Colombia, Bogotá, Colombia., Galvis I; Rheumatology Service, Samaritana University Hospital - ESE, Bogotá, Colombia.; Radiology Program, La Sabana University, Chia, Coloumbia., Patiño M; Dermatology Service, Samaritana University Hospital - ESE, Bogotá, Colombia., Velasquez O; Dermatology Service, Samaritana University Hospital - ESE, Bogotá, Colombia.; Dermatology Program, National University of Colombia, Bogotá, Colombia.
Jazyk: angličtina
Zdroj: International journal of dermatology [Int J Dermatol] 2017 Dec; Vol. 56 (12), pp. 1379-1386. Date of Electronic Publication: 2017 Oct 09.
DOI: 10.1111/ijd.13755
Abstrakt: Background: Relapsing polychondritis is an autoimmune multisystemic disease with primary chondral involvement. Its high mortality and morbidity make it a real clinical challenge.
Case Description: A 32-year-old woman with a history of relapsing polychondritis, refractory to multiple treatments, with multisystem compromise, imminent risk of death due to severe tracheobronchial damage and difficult ventilatory support, and successful treatment with infliximab.
Discussion and Evaluation: Several treatments have been described in the literature, such as nonsteroidal anti-inflammatory drugs, corticosteroids, dapsone, azathioprine, cyclosporine, cyclophosphamide, and methotrexate. However, the cases refractory to conventional therapy may lead to chronicity, irreversibility, and death. As a result, a third-line therapy could improve the prognosis of these patients.
Conclusions: Biological therapy is a good option for disease control and quality of life improvement. In addition, the physician should consider these treatments to avoid the chronicity and risk of death of these patients.
(© 2017 The International Society of Dermatology.)
Databáze: MEDLINE
Externí odkaz: